Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

disitamab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Muscle Invasive Bladder Carcinoma × Clear all
NCT05297552 2024-02-20

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

RemeGen Co., Ltd.

Phase 2 Unknown
40 enrolled

Muscle Invasive Bladder Carcinoma

NCT06074484 2023-10-10

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
36 enrolled

Muscle Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡